Parsippany, New Jersey-based Onkos Surgical has raised $15 million in Series C funding.
Onkos Surgical Raises $15M in Series C Funding
1 min read Premium comments
#onkossurgicalSecondary
Founded in 2015, Onkos Surgical creates “innovative solutions for musculoskeletal oncology and complex orthopaedic procedures.” According to the company, its products GenVie™, My3D™, uDesign™, ELEOS™ Limb Salvage System, and MyTray™ address limb salvage and custom 3D limb repair.
The funding came from the company’s existing investors: Philadelphia based 1315 Capital, a private investment firm; San Francisco based Canaan, an early-stage venture capital firm; and Rock Hill, South Carolina-based 3D Systems, an additive manufacturing solutions partner.
According to the company, the funding will be used for Onkos Surgical research and development (R&D) pipeline, commercial expansion, and manufacturing operations, and the “clinical challenges of complex orthopaedic procedures” including “implant loosening, soft tissue failures, and infection.”
Onkos Surgical Co-Founder and CEO Patrick Treacy discussed the funding with OTW: “Our recent investment will allow us to accelerate innovation in three key areas: 1) the management of metastatic bone disease, 2) simplifying complex procedures through the application of digital surgical planning and 3D printed personalized patient solutions, and 3) commercialization of a novel antimicrobial implant technology.”
Treacy continued, “Acceleration of the R&D pipeline will enable Onkos to expand our current customer base and open up opportunities for new market segments with differentiated technology that will help surgeons improve outcomes in complex orthopedic cases.”
“The additional funds will allow Onkos to optimize in-house manufacturing strategies and partnerships for our personalized product solutions and antimicrobial technology that will improve the speed and flexibility of our supply chain. These investments will provide our customers and the patients they care for with game changing technology with world class delivery times.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.